TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05547750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Description: Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar-looking placebo tablets
Study: NCT05608941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: The training program will be carried-out with the Orygen Dual Valve. Individuals will perform a home-based intervention, split into two daily 20-min sessions (morning and afternoon), totaling 40 min per day, seven times a week, during eight weeks. Each daily session will be composed into four blocks of three minutes, with a two-minute rest between blocks. The initial training load for each participant will be set at 60% of his/her maximal baseline MIP and MEP for both inspiratory and expiratory strength training, respectively. Borg score of dyspnea and effort was also considered for adjusting training intensity, and scores from 4 to 6 were targeted. Once a week, a trained researcher will visit their homes, the MIP and MEP will be evaluated and the training load will be progressed to ensure that 60% of the new pressure values are maintained.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
Study: NCT05574075

Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion tensor imaging
Description: white matter imaging markers
Study: NCT06138639

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-003
Description: Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-003
Description: Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)
Study: NCT05799053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Small intestinal release peppermint oil
Description: Tempocol®, a gastric acid resistant (enteric-coated) capsule containing 182mg of Menthae Piperitae Aetheroleum (peppermint oil), is currently registered as an over the counter prescription drug on the Dutch market for treatment of abdominal pain, discomfort or flatulence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint sweets
Description: Wilhelmina® peppermints contain 9.2 mg of Menthae Piperitae Aetheroleum (peppermint oil), and 18.4 Kcal per mint and are to be taken orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing microcrystalline cellulose
Study: NCT06273527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGENT
Description: COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Program
Description: The Sham Program will be a similar task which researchers think will be less effective in training thinking skills.
Study: NCT04648891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Subcutaneous injection 0.5cc 2% in 1:100,000 epinephrine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating wand
Description: a vibrating instrument held adjacent to the cricothyroid space
Study: NCT05215262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treat Act Know Engage (T.A.K.E.) Steps
Description: Intervention sessions will consist of psychoeducation, HIV/STI goal identification, referral to HIV testing and PrEP, and communication skill building.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard or Care
Description: S.O.C. arm will receive treatment as usual. After the baseline interview, participants will be referred to their PCP for management of any clinical issues that arise. Their clinic visit schedule will follow their clinical needs and recommendations of their clinic provider
Study: NCT05942469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOREST
Description: The skill sessions will include didactic content defining the skill, rationale for including the skill in FOREST, and research demonstrating that practice of the skill increases positive emotion. In addition, the group will practice the skill together and will discuss ways to practice the skill at work as well as outside of work. Throughout the month, PEAs will implement the FOREST skill of the month in other existing meetings, check-ins, and team outings.~Concurrently, a module in UCAN's learning management system (LMS) will become available. The LMS modules will contain skill-related content similar to what is taught in the skill sessions, including a thorough definition of the skill, examples of ways to utilize the skill, a review or summary of the skill, and several knowledge questions to check for comprehension. The LMS content may include text, audio, images, and video components.
Study: NCT04861571

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention with very low calorie diet (VLCD)
Description: The VLCD program will last 8 weeks. The only sources of nutrition during this phase are the Optifast® products providing up to 800 kcal per day. Two liters (67.63 fl oz) of water should also be consumed each day. Participants will be instructed to use 5 replacement meals per day (800 kcal total) with 40% of calories as protein, 40% as carbohydrate, and 20% as fat.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Arm
Description: The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
Study: NCT04754529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Receive yoga intervention
Study: NCT05761444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atozet 10/40 mg or 10/80 mg
Description: Atozet 10/40 mg or 10/80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipitor 40 mg or 80 mg
Description: Lipitor 40 mg or 80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
Study: NCT06463340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGR-3515
Description: SGR-3515 will be administered orally with an intermittent schedule.
Study: NCT06425029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Intervention (Music A)
Description: Participants will be asked to listen to Music A on their personal device daily, at a time most convenient for them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Intervention (Music B)
Description: Participants will be asked to listen to music B on their personal device daily, at a time most convenient for them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Intervention (Music C)
Description: Participants will be asked to listen to music C on their personal device daily, at a time most convenient for them.
Study: NCT06466915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Group Dex received 1 mcg/kg of dexmedetomidine intra-nasal 10 minutes before the surgical procedure ended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Group Dex received 1 mcg/kg of dexmedetomidine intra-nasal 10 minutes before the surgical procedure ended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Group Pofol received 1 mg/kg propofol IV before the extubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Group Pofol received 1 mg/kg propofol IV before the extubation.
Study: NCT04813146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLP
Description: Synchronization of dietary intake with circadian rhythm of the body

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLP along with Physiotherapy
Description: Synchronization of dietary intake along with Physiotherapy (aerobic, flexibility, resistance and balance exercises)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy given only (aerobic, flexibility, resistance and balance exercises)
Study: NCT04686305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: T-DXd: administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion
Study: NCT04394559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-Led Discharge Counseling and Communication
Description: Two visits by a trained inpatient pharmacist, including an intake visit to determine previous barriers to safe medication use, and a discharge counseling session with patients and caregivers regarding safe and effective opioid use after discharge; pharmacist communication with providers regarding the post-discharge pain management plan.
Study: NCT04686305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed: administered as an IV infusion (drug not used)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Volrustomig: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Volrustomig: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig: administered as an IV infusion
Study: NCT06512805

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine transport
Description: 1. Before the transfer of the patient:~   ① The doctor determines the destination of the patient based on the patient's condition and issues transfer orders.~  * The responsible nurse assesses the patient's consciousness, circulation, respiration, etc., and fills out the Transfer Patient Handover Record in the transferring department section.~     * The responsible nurse prepares the equipment, medications, and patient's belongings required for the transfer.~2. During the transfer:~   Monitor the patient's vital signs.~3. Upon arrival at the receiving department:~   * Place the patient with the receiving department nurse. ② Verbally hand over the patient's condition to the receiving department nurse and hand over the patient's belongings and medications.~     * The responsible nurse of the receiving department completes the remaining part of the Transfer Patient Handover Record.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-guideline transfer
Description: In the intervention group, nurses receive implementation strategies developed during the preparation phase. These strategies aim to modify the behavior of healthcare personnel through implementation, thereby conducting evidence-based (based on the guidelines) in-hospital transfer interventions for pediatric patients.The interventions received by pediatric patients are derived from the recommended practices evaluated for evidence availability in the guidelines. These include specific transfer procedures, the Transfer Risk Level Classification Criteria, Personnel Qualifications, Equipment, and Medications Allocation Based on Transfer Risk Level, Transfer Preparation Checklist, and Transfer Handover Checklist 2.0.
Study: NCT06418295

Intervention type: OTHER
Intervention: Unilateral thoracotomy
Description: Unilateral thoracotomy to proceed as per standard of care guidelines. Thoracic epidural analgesia, or patient controlled analgesia (PCA) pumps will be offered to each study participant as per standard of care. Pre- and post-operative (post-operative day 1 and 3 months) pain scores and blood samples will be collected. Blood samples will be analyzed to determine the concentration of cytokines, chemokines, and growth factors that are potentially associated with CPSP (epidermal growth factor, eotaxin, fibroblast growth factor basic, G-CSF, GM-CSF, human growth factor, IFN-α, IFN-γ, IL-1ra, IL-1β, IL-2, IL-2r, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, and VEGF). DNA promotor methylation for these targets will also be investigated.
Study: NCT06176989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: 100mg PO (orally) once daily, on days 1-28 of a 28-day cycle
Study: NCT06444763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maolactin
Description: Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
Study: NCT04394559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-discharge Pain Management Follow-up
Description: An outpatient pharmacist pain management follow-up visit (with additional contact as needed) embedded within routine post-operative care for managing pain and opioid use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Engagement Pain Management App
Description: A mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder.
Study: NCT06444763

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
Study: NCT05311982

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC-R (F4) TDCS
Description: direct current brain stimulation- The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A), combined tDCS in DLPFC-L (F3) and DLPFC-R (F4) simultaneously (Block B) or sham-tDCS (Block C) with equal electrode configuration guaranteed blindness. After the procedures, each participant received the following intervention in the order ABC, BCA or CAB with a period of 1 week between each one. Each block took 3 weeks, organized into: 1) Assessment; 2) Application of stimulation; 3) Reassessment and washout week. Adding 1 more week of final evaluation, the study totaled the period of 10 weeks. During this period, patients were instructed to continue their behavioral/educational treatment and medication routines.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC-R (F4) TDCS
Description: direct current brain stimulation- The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A), combined tDCS in DLPFC-L (F3) and DLPFC-R (F4) simultaneously (Block B) or sham-tDCS (Block C) with equal electrode configuration guaranteed blindness. After the procedures, each participant received the following intervention in the order ABC, BCA or CAB with a period of 1 week between each one. Each block took 3 weeks, organized into: 1) Assessment; 2) Application of stimulation; 3) Reassessment and washout week. Adding 1 more week of final evaluation, the study totaled the period of 10 weeks. During this period, patients were instructed to continue their behavioral/educational treatment and medication routines.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC-L (F3) and DLPFC-R (F4) TDCS
Description: DLPFC-L (F3) and DLPFC-R (F4) (Bock B)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC-L (F3) and DLPFC-R (F4) TDCS
Description: DLPFC-L (F3) and DLPFC-R (F4) (Bock B)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham-tDCS
Description: sham-tDCS (Block C) with equal electrode configuration guaranteed blindness

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham-tDCS
Description: sham-tDCS (Block C) with equal electrode configuration guaranteed blindness
Study: NCT06132503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-284
Description: LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.
Study: NCT05892861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive stimulation
Description: video education, board games, and 24-hour dietary recall record

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: as usual care
Description: history taking, explain data, and discuss how to control healthy condition
Study: NCT05628961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOPO 14-1
Description: HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
Study: NCT06013163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMP 16 vs Xenical®
Description: Each participant will receive a single dose of EMP16 and then a single dose of Xenical®.
Study: NCT05341180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol
Description: Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Polyethylene glycol syrup at a dose of 15-30 ml will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isabgol + Lactulose
Description: Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Isabgol husk at a dose of 2 teaspoons in 200 ml of warm water before bedtime and 30 ml of syrup lactulose at bedtime will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
Study: NCT06312462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health education
Description: In the intervention group, we provide schistosomiasis health education to students once a month through community health volunteers for a duration of six months. After that, the community health volunteers no longer visit the school for health education until the completion of a one-year follow-up period.
Study: NCT04416750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Treatment with Imatinib
Study: NCT06180915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days.
Description: The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days. The peer educator will create a Whatsapp group with the experimental group participants and a name for the group will be found by mutual decision. The peer educator will schedule a time and date with the group. Each session will last approximately 60 minutes and the total training duration will be planned to be 3 weeks. One week and one month after the training is completed, the participants will fill out the scales again.
Study: NCT05203692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7011a
Description: Intravenous or subcutaneous administration, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous or subcutaneous administration, single dose
Study: NCT04058977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power training
Description: Progressive exercise protocol with focus on velocity of movement
Study: NCT05457868

Intervention type: DRUG
Intervention: Salbutamol
Description: Salbutamol claim is used as the exposure group.

Intervention type: DRUG
Intervention: LAMA
Description: Long-acting muscarinic antagonists (LAMA) - umeclidinium, aclidinium, tiotropium, glycopyrolate, glycopyrronium - claim is used as the reference group.
Study: NCT04662476

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 supplement